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Although astrogliosis and microglia activation are characteristic features of multiple
sclerosis (MS) and other central nervous system (CNS) lesions the exact functions
of these events are not fully understood. Animal models help to understand the
complex interplay between the different cell types of the CNS and uncover general
mechanisms of damage and repair of myelin sheaths. The so called cuprizone model
is a toxic model of demyelination in the CNS white and gray matter, which lacks an
autoimmune component. Cuprizone induces apoptosis of mature oligodendrocytes that
leads to a robust demyelination and profound activation of both astrocytes and microglia
with regional heterogeneity between different white and gray matter regions. Although
not suitable to study autoimmune mediated demyelination, this model is extremely
helpful to elucidate basic cellular and molecular mechanisms during de- and particularly
remyelination independently of interactions with peripheral immune cells. Phagocytosis
and removal of damaged myelin seems to be one of the major roles of microglia in this
model and it is well known that removal of myelin debris is a prerequisite of successful
remyelination. Furthermore, microglia provide several signals that support remyelination.
The role of astrocytes during de- and remyelination is not well defined. Both supportive
and destructive functions have been suggested. Using the cuprizone model we could
demonstrate that there is an important crosstalk between astrocytes and microglia. In
this review we focus on the role of glial reactions and interaction in the cuprizone model.
Advantages and limitations of as well as its potential therapeutic relevance for the human
disease MS are critically discussed in comparison to other animal models.
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INTRODUCTION
Demyelination of the central nervous system (CNS) is the
hallmark of diseases like multiple sclerosis (MS). MS is gen-
erally considered to be an autoimmune disease, however, the
causative agent of MS and a possible trigger of this disorder
are still not well understood. The pathology of MS lesions is
heterogeneous (Lucchinetti et al., 2000) and several patterns
suggesting predominant immune-mediated inflammation (pat-
tern I and II) and primary oligodendrogliopathy (pattern III
and IV) have been described (Lucchinetti et al., 1996, 2000).
Although remyelination frequently occurs after demyelinating
events, it is often incomplete (Patrikios et al., 2006; Goldschmidt
et al., 2009). Thus, one of the challenges of MS research is
to understand remyelination failure and develop strategies to
restore myelin. Animal models are a helpful tool to reveal
mechanisms underlying de- and remyelination and to study the
cellular response and interplay during these processes, thus pro-
viding a solid platform to elucidate putative therapeutic targets.
There are four well-characterized experimental approaches to
induce demyelination in the rodent CNS: genetic myelin muta-
tions, autoimmune inflammatory-induced demyelination [exper-
imental autoimmune encephalomyelitis (EAE)], viral-induced
demyelination, genetic models, and toxic demyelination. It
needs to be emphasized that all these models, including EAE,
mimic only a part of MS pathology. Although EAE is proba-
bly the most commonly used model that reflects the autoim-
mune origin of MS, toxic demyelination is more appropriate
to study remyelination. Here, cuprizone-induced intoxication
has gained a lot of attention and acceptance in recent years
(Matsushima and Morell, 2001; Kipp et al., 2009; Skripuletz
et al., 2011a). Cuprizone [bis–cyclohexanone-oxaldihydrazone] is
a copper chelating reagent, which supplemented to normal rodent
chow, directly or indirectly causes oligodendroglial cell death
with subsequent demyelination. Once demyelination is complete
new oligodendrocytes, generated from the pool of oligoden-
drocyte progenitors (OPC), begin to form new myelin sheaths.
Remyelination rapidly progresses after termination of the cupri-
zone diet (acute demyelination, Figure 1). When cuprizone is fed
continuously remyelination is abortive and demyelination per-
sists till the end of the diet (chronic demyelination). In this case
the remyelination capacity retains after withdrawal from cupri-
zone diet but is strongly decreased (Ludwin, 1980; Lindner et al.,
2009). Microgliosis and astrogliosis, driving inflammatory but
also reparative processes in the face of an intact blood–brain bar-
rier (BBB), are prominent features of this animal model (Carlton,
1966; Blakemore, 1973a; Bakker and Ludwin, 1987; Kondo et al.,
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1987; Hiremath et al., 1998; Matsushima and Morell, 2001;
Remington et al., 2007; Gudi et al., 2009). Thus, the cuprizone
model is a suitable tool to study basic glial reactions and inter-
actions during de- and re-myelination in absence of primarily
immune-mediated mechanisms.
THE CUPRIZONE MODEL-A HISTORICAL EXCURSION
The history of the cuprizone model spans more than 50 years.
The copper chelator cuprizone was first used in clinical chemistry
for quantitative analysis of copper content in biological mate-
rials such as serum and plasma (Peterson and Bollier, 1955).
The attention for this compound was drawn by the findings
of Carlton that cuprizone possesses various biotoxic effects in
rodents like growth retardation, pregnancy disturbances, and
severe CNS pathology, including demyelination, astrogliosis, and
hydrocephalus (Carlton, 1966, 1967, 1969). Administration of
cuprizone at dietary levels of 0.2–0.5% (w/w) in standard rodent
chow to mice produced brain oedema, spongiform encephalopa-
thy, characterized by numerous enlarged vacuoles (intracellular
and intramyelinic) and creating a morphologic picture similar to
that of scrapie (Suzuki and Kikkawa, 1969; Hemm et al., 1971;
Kesterson and Carlton, 1971; Pattison and Jebbett, 1971a,b). In
1972 Blakemore described a massive depletion of oligodendro-
cytes as a primary reason for cuprizone-induced demyelination
(Blakemore, 1972). He also reported about remyelination, which
can occur spontaneously after removal of the cuprizone diet
(Blakemore, 1973b) and established cuprizone feeding as a model
to study de- and remyelination in the superior cerebellar peduncle
(Blakemore, 1973a). At that time the cerebellar peduncle became
the most investigated area in this animal model. In 1980 Ludwin
established a chronic model of demyelination by feeding mice up
to 6–7 months with cuprizone-containing chow (Ludwin, 1980).
He showed that the remyelination capacity was retained but
massively impaired after a long toxic insult, suggesting that the
pool of remyelinating cells is limited. Similar results were reported
after repeated cuprizone treatments (Johnson and Ludwin, 1981).
The next 17 years only few papers concerning cuprizone were
published. Moreover, most of these studies were focused on alter-
ations of liver mitochondria (mega-mitochondria, first described
by Suzuki, 1969) induced by cuprizone. In 1998 the cupri-
zone animal model experienced a comeback as the group of
Matsushima (Hiremath et al., 1998) characterized cuprizone-
induced de- and remyelination in the corpus callosum (CC) of
C57BL/6 mice. In this pioneer work Hiremath et al. determined
some crucial points for this model, such as age (8–10 weeks) of
animals, dose [0.2% (w/w) in powdered standard rodent chow],
and duration of treatment (5–6 weeks). They also described the
glial reaction upon cuprizone treatment and showed that the
extent of demyelination in the CC, as detected by histologi-
cal staining, could be easily scored, providing investigators with
a reproducible and well predictable animal model for de- and
remyelination. Since then the CC is the most frequently inves-
tigated white matter tract. The use of C57BL/6 mice opened
the investigators a lot of new possibilities to study genetically
modified mice.
Remarkably, the susceptibility to cuprizone, extent of hydro-
cephalus, spatiotemporal pattern of de- and remyelination or the
glial reaction are varying between species, mice strains or sim-
ply between different brain regions (Carlton, 1969; Kimberlin
et al., 1976; Love, 1988; Stidworthy et al., 2003; Adamo et al.,
2006; Skripuletz et al., 2010a), suggesting that the local cellular
microenvironment can promote or prevent deleterious effects of
cuprizone and demyelination and remyelination.
The dose of cuprizone is one of the most important factors
to induce demyelination in the murine CNS. The first inves-
tigators applied a diet of 0.2–0.6% (w/w) cuprizone to differ-
ent mouse strains (Carlton, 1967; Kesterson and Carlton, 1971;
Ludwin, 1980), however, toxic effects such as hydrocephalus and
the lethality were very high in these experiments. Hiremath et al.
investigated different cuprizone dosages for C57BL/6 mice. They
showed that 0.1% (w/w) cuprizone supplemented to normal
rodent chow did not lead to an extensive demyelination in the
CC of C57BL/6 mice, while mice fed 0.3–0.5% cuprizone dis-
played severe weight loss and high mortality (Hiremath et al.,
1998). Thus, 0.2% (w/w) cuprizone was established to induce
highly reproducible and extensive demyelination without detri-
mental systemic effects in 8–10 weeks old mice. However, the
susceptibility to cuprizone seems to differ between young and
old animals and between different mouse strains (Carlton, 1967;
Blakemore, 1973b; Irvine and Blakemore, 2006). Axonal dam-
age and glial response accompanying demyelination were more
severe and prolonged in aged (6–7 months) as compared to
young (8–10 weeks) mice (Irvine and Blakemore, 2006). The
reason for the age-dependent susceptibility to cuprizone is cur-
rently not clear. Remyelination readily occurs in older animals but
seems to be delayed or less efficient (Blakemore, 1974; Irvine and
Blakemore, 2006), a finding also seen in other de-/remyelination
models (Shields et al., 1999; Hinks and Franklin, 2000; Sim et al.,
2002). This phenomenon may be attributed to a reduced capac-
ity of progenitor cells to replace oligodendrocytes probably due
to an altered age-related expression of certain transcription factor
such as Nkx2.2 (Doucette et al., 2010) or due to an inefficient
age-dependent epigenetic modulation, as shown by a declined
recruitment of histone deacetylases (HDACs) to promoter regions
of oligodendrocyte differentiation inhibitors (Hes1, Hes5, Id2,
and Id4) and neural stem cell markers such as Sox2 followed
by insufficient deacytelation of nucleosomal histones and subse-
quent perturbances of myelin gene expression in older mice (Shen
et al., 2008).
The gender-related differences in de- and remyelination pat-
tern were already mentioned by Ludwin who notified that Swiss
female mice did not undergo demyelination (Ludwin, 1978). The
demyelination pattern of SJL mice differed from that in C57BL/6
(Taylor et al., 2009). Additionally, despite of a similar extent of
astro- and microgliosis as well as OPC response in both gen-
ders, female SJL mice were partially resistant to the demyelination
in the CC. In contrast, the course of de- and remyelination was
similar between genders in C57BL/6 mice (Taylor et al., 2010).
In the last decade it has become accepted that MS lesions
arise also within gray matter structures, particularly in the cor-
tex (Kidd et al., 1999; Bo et al., 2003). Cortical demyelination
can be observed after 3 weeks of cuprizone exposure being almost
complete after 6 weeks of cuprizone treatment (Skripuletz et al.,
2008; Gudi et al., 2009). Furthermore, demyelination may also be
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FIGURE 1 | The course of de- and remyelination in the medial
corpus callosum. 8–10 weeks old C57BL/6 mice were fed with 0.2%
(w/w) cuprizone for 5 weeks. During the “early demyelination” (1–3
weeks) the degradation of myelin proteins begins and can be hardly
detectable using immunohistochemical techniques. After week 3
onwards demyelination progresses (“severe demyelination”) and is
complete at week 5 (“complete demyelination”). Remyelination starts
immediately thereafter. Between weeks 5 and 6 numerous remyelinated
axons appear in the medial corpus callosum (“early remyelination”). We
therefore, suggest to stop the cuprizone administration after 5 weeks
to allow newly generated oligodendrocytes to restore myelin sheaths
without any influence of cuprizone.
detected in other brain regions such as hippocampus, basal gan-
glia, and cerebellum (Koutsoudaki et al., 2009; Pott et al., 2009;
Skripuletz et al., 2010a).
MODE OF CUPRIZONE ACTION
Despite the experimental use of cuprizone for almost five decades
the underlying mechanism of oligodendrocyte damage is still
not completely understood. The copper-chelating property of
cuprizone seems to be an obvious explanation. However, copper
administration (100 ppm) synchronously to cuprizone adminis-
tration (0.5%) did not reduce the toxic effects (Carlton, 1967).
When mice were fed 0.2% (w/w) cuprizone and copper sup-
plementation was increased to 130ppm the incidence of hydro-
cephalus declined without any effects on brain oedema and
spongy degradation (Carlton, 1967). These observations pointed
to a more complex mode of action that is not only based on
the copper-chelating properties but may also regulate other cel-
lular processes. Unfortunately, it is not really known whether
cuprizone undergoes metabolic transformation in the organism.
Extracted liver mitochondria were not affected by cuprizone ex
vivo (Hoppel and Tandler, 1973). However, mitochondrial distur-
bances seem to be the key factor of oligodendroglial apoptosis,
since enlarged “giant” mitochondria were detected in the liver
and brain of cuprizone-treated mice (Suzuki, 1969; Hemm et al.,
1971; Komoly et al., 1987). Additionally, the activities of a batch
of mitochondrial enzymes containing copper as a co-factor were
altered during first days/weeks of cuprizone treatment. In fact,
the activity of carbonic monoamine oxidase (MAO), which is
localized on the outer mitochondrial membrane, was inhibited
already after 3 days on cuprizone diet and progressed to almost
total inhibition in the brain until week 5 (Kesterson and Carlton,
1971; Venturini, 1973). Furthermore, the activity of cytochrome
c oxidase, a terminal acceptor of the electron transport chain was
as well decreased followed cuprizone administration (Venturini,
1973), while succinate dehydrogenase activity was increased in
both liver and brain tissue. Within this context, Pasquini et al.
reported a marked decrease in the activities of complex I, II, and
III of the respiratory chain in oligodendrocyte cultures treated
with cuprizone and in mitochondria isolated from cuprizone-
treated mice confirming that cuprizone disturbs mitochondrial
function and thus compromises the energy metabolism of cells
(Pasquini et al., 2007). Recently, a strong reduction of the mito-
chondrial potential was also reported in cuprizone-treated oligo-
dendrocytes in vitro (Benardais et al., 2013). It remains unclear
why mature oligodendrocytes are preferentially vulnerable to
cuprizone. A regular function of mitochondria is essential for
oligodendroglial survival. Due to an extensive membrane synthe-
sis oligodendrocytes need to display a high cellular metabolism
requiring a large amount of oxygen and adenosintriphosphat
(ATP). For instance, during myelination oligodendrocytes gen-
erate three times of their weight into the membrane per day
and can support myelin membranes approximately 100 times the
weight of their cell body (McTigue and Tripathi, 2008; Bradl and
Lassmann, 2010). Furthermore, oligodendrocytes possess only a
little amount of the anti-oxidative enzyme, glutathione, which
also declines upon cuprizone treatment, but in comparison to
other brain cells the highest amount of iron (Thorburne and
Juurlink, 1996; Biancotti et al., 2008). Oligodendrocytes require
iron due to intensive oxidative metabolism and as a co-factor for
cholesterol and lipid biosynthesis for myelin production (Connor
and Menzies, 1996; Thorburne and Juurlink, 1996). Previously,
it was discussed that cuprizone may not be selective only for
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copper but can also chelate other heavy metals such as zinc,
iron, and manganese and thus, impairs functions of additional
important enzymes such as cytosolic zinc containing enzyme,
anhydrase II (CA II) (Hoppel and Tandler, 1973). Besides being
responsible for base-acid homeostasis, CA II is suggested to be
involved in myelin metabolism and compaction since it is also
activated during developmental myelination (Delaunoy et al.,
1980; Ghandour et al., 1980; Komoly et al., 1987). The vast major-
ity of the brain CA II is localized in the oligodendrocytes and the
myelin (Cammer et al., 1985; Komoly et al., 1987). The activity of
CA II started to decline already during the first week of cuprizone
diet well before demyelination develops and (Komoly et al., 1987)
persists until demyelination is complete.
In the light of all these evidences it is obvious that cuprizone
directly or indirectly impairs a variety of essential cell functions.
However, mitochondria seem to be mainly affected by this toxin,
leading to increased production of oxidative agents, and distur-
bance of energy metabolism of oligodendrocytes with subsequent
cell death. Additionally, since cuprizone susceptibility depends on
a variety of co-factors such as age, strain, genetic background,
dose, and duration of exposure, the mode of action seems to be
a complex mechanism requiring multiple steps and interplayers.
Inflammatory metabolites of activated microglia/astrocytes may
harm oligodendrocytes as well.
GLIAL REACTIONS DURING CUPRIZONE-INDUCED DE- AND
REMYELINATION
THE FATE OF OLIGODENDROCYTES
During cuprizone-induced demyelination, oligodendrocytes start
to undergo apoptosis after 3–7 days of cuprizone exposure
(Mason et al., 2000a; Komoly, 2005; Hesse et al., 2010). Big
vacuoles, enlarged mitochondria, and dense nuclear chromatin
were observed at this time in oligodendrocytes by electron
microscopy (Blakemore, 1972; Ludwin, 1978; Komoly, 2005).
The mRNA expression of myelin protein genes, such as pro-
teolipid protein (PLP), myelin-associated glycoprotein (MAG),
and myelin basic protein (MBP) is dramatically down-regulated
already at week 1 (Morell et al., 1998; Gudi et al., 2011).
Immunohistochemically, apoptotic oligodendrocytes could be
characterized by activation of caspase-3 und positive Tunel-
staining. Interestingly, caspase-3-positive oligodendrocytes were
detected in the CC only during the first 10 days of cuprizone diet.
After 3 weeks of cuprizone diet the same amount of dying oligo-
dendrocytes was detected in CC only via Tunel-stainig (Hesse
et al., 2010), suggesting that at this time a caspase-3-independent
apoptosis predominates. Veto et al. investigated apoptosis after
3 weeks of cuprizone diet and similar to Hesse et al. did not
see any activation of caspase-3. Instead, they observed activation
of poly(ADP-ribose) polymerase (PARP) and nuclear transloca-
tion of apoptosis-inducing factor (AIF), confirming caspase-3-
independent apoptosis (Veto et al., 2010). Thus, it seems that
initially oligodendrocytes are dying due to caspase-3-dependent
apoptosis, while later caspase-3-independent apoptosis predom-
inates. Similarly, enhanced PARP activation and induction of
caspase-independent apoptosis were also described for pattern
III MS lesions with primary oligodendrogliopathy (Veto et al.,
2010). This is one of the reasons why the cuprizone model is
more and more referred to as an animal model for MS pattern
III (Torkildsen et al., 2008; Kipp et al., 2009; Liu et al., 2010; Veto
et al., 2010; Acs and Komoly, 2012; Kang et al., 2012; Silvestroff
et al., 2012). However, it always has to be kept in mind, that
cuprizone-induced oligodendroglial cell death followed bymyelin
clearance is an artificial event directly or indirectly caused by this
toxin. The oligodendroglial depletion in MS seems to progress
in an apoptosis–like manner with expression of some apop-
totic markers, such as bcl-2, p53, p75NTR (Dowling et al., 1996;
Kuhlmann et al., 1999; Wosik et al., 2003). The transcription fac-
tor p53 is a well characterized pro-apoptotic molecule activated
in response to a wide variety of toxic stimuli (Giaccia and Kastan,
1998). Li and colleagues reported that elevated levels of p53 can be
detected in the CC of mice during the first 2–3 weeks of cuprizone
diet. P53-deficient mice and mice systematically receiving the
p53 inhibitor pifithrin are less susceptible to cuprizone-induced
demyelination and show an enhanced oligodendrocytic survival
(Li et al., 2008).
p75NTR is a neurotrophin receptor, which can induce differ-
ent cellular responses, including cell growth but also apoptosis.
p75NTR was up-regulated in the CC between day 10 and 20 of
cuprizone feeding and was expressed only in oligodendrocytes.
Remarkably, no simultaneous expression of p75NTR and caspase-
3 could be detected (Copray et al., 2005). Since p75NTR −/−
mice did not show any alteration regarding the course of de-
and remyelination or glial reactions it is obvious that p75NTR
does not play a major role in the induction of apoptosis in the
cuprizone model.
FAS, an activator of the extrinsic apoptotic cell cascade, has
been described as a key molecule for oligodendroglial cell death
in EAE (Hovelmeyer et al., 2005). Upon cuprizone treatment FAS
mRNA expression level was up-regulated during the first 2 weeks
in the CC and thus, correlates with the expression pattern of acti-
vated caspase-3 in oligodendrocytes. However, oligodendrocyte
death was not prevented in mice lacking FAS in oligodendro-
cytes revealing that FAS is also not essential for the induction
of apoptosis in the cuprizone model (Hesse et al., 2010). After
3 weeks of cuprizone treatment mature oligodendrocytes are
almost completely depleted (Hesse et al., 2010; Skripuletz et al.,
2011b). From this time point onward progressing demyelination
can be observed in the CC and the cortex visualized by histo-
logical and immunohistochemical techniques (Hiremath et al.,
1998; Morell et al., 1998). Demyelination peaks between 4.5
and 5 weeks of cuprizone exposure in the CC and between 5
and 6 weeks in the cortex and hippocampus (Hiremath et al.,
1998; Matsushima and Morell, 2001; Skripuletz et al., 2008; Gudi
et al., 2009; Koutsoudaki et al., 2009). Cerebellar gray and white
matter shows severe demyelination after 12 weeks of cuprizone
feeding (Skripuletz et al., 2010a). It is important to mention
that degradation/re-expression of different myelin proteins (at
least in the CC and as depicted by immunohistochemistry) fol-
lows individual temporal pattern (Gudi et al., 2009). Complete
demyelination in the medial CC can be observed by PLP staining
at week 5, however, using CNPase- and MBP-antibodies already
at week 4–4.5 of cuprizone feeding (Gudi et al., 2009).
Successful remyelination comprises several highly orchestrated
events includingmigration, proliferation, terminal differentiation
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of OPC, and myelination (Stangel and Hartung, 2002). These
repair mechanisms start very early even before demyelination can
be detected immunohistochemically. Upon cuprizone-induced
demyelinationNG-2-positive precursor cells proliferate and accu-
mulate in the subventricular zone (SVZ) at week 2 and then
migrate towards demyelinating lesions (Mason et al., 2000a).
The basic helix-loop-helix (bHLH) transcription factors Olig1
and Olig2 have been revealed to play a key role in regulat-
ing oligodendrocyte development (Zhou et al., 2000; Lu et al.,
2001; Zhou and Anderson, 2002; Ligon et al., 2006). Whereas
Olig2 is required for the determination of oligodendrocytes at
early stages, Olig1 plays additionally a reparative role and is
particularly essential for oligodendrocyte differentiation and con-
sequent remyelination (Zhou et al., 2000; Takebayashi et al., 2002;
Arnett et al., 2004). Initially identified as a downstream effec-
tor of Olig1, an oligodendrocyte specific zinc finger transcription
repressor, Zfp488, was shown to interact with Olig2 physically
in vitro and thus, being involved in the transcriptional network
of Olig2 action (Wang et al., 2006). Soundarapandian et al.
demonstrated that retrovirus-mediated Zfp488 over-expression
could significantly promote an oligodendrogenic fate of dif-
ferentiating SVZ neuronal stem cells and enhance functional
recovery of cuprizone-treated mice (Soundarapandian et al.,
2011).
Parallel to the myelin clearance in the CC (3–5 weeks of cupri-
zone administration) local and migrated OPC start to proliferate
within lesions (Mason et al., 2000a; Gudi et al., 2009; Skripuletz
et al., 2011b). Thereafter (up to week 5) OPC begin their termi-
nal differentiation and restore myelin sheaths. Numerous newly
generated APC/Nogo-A-positive mature oligodendrocytes can be
observed from week 5.5 (0.5 weeks after the end of cuprizone
feeding) in the CC (Koutsoudaki et al., 2010). On the mRNA
level MBP or PLP returns to normal levels between weeks 5 and 6
(Morell et al., 1998; Gudi et al., 2011). On the protein level, newly
remyelinated axons could be detected with anti-CNPase and
-MBP already from week 5 and with anti-PLP and -MOG anti-
bodies fromweek 5.5 to 6 (Gudi et al., 2009; Moharregh-Khiabani
et al., 2010; Skripuletz et al., 2010b, 2013). Remyelination is very
robust in the cuprizone model and starts directly after demyeli-
nation is complete, irrespective if cuprizone is further fed or
not (Matsushima and Morell, 2001; Hiremath et al., 2008; Gudi
et al., 2009). It seems that in the case of continued cuprizone
feeding until week 6 newly generated oligodendrocytes are dam-
aged again. Recently we have shown that especially differentiated
oligodendrocytes but not OPC are affected by cuprizone in vitro
(Benardais et al., 2013). Thus, in order to study remyelination
in the CC it is recommended to administer cuprizone for 5
weeks to exclude any interference of beginning remyelination with
cuprizone.
Upon chronic cuprizone administration (12–16 weeks) newly
generated oligodendrocytes progressively undergo apoptosis.
Furthermore, also the pool of OPC becomes diminished (Mason
et al., 2004). Nevertheless, demyelinated axons retain the ability
to be remyelinated as shown by transplantation of OPC into the
lesions (Mason et al., 2004). However, the remyelination capacity
was clearly reduced after the withdrawal of cuprizone (Ludwin,
1980; Lindner et al., 2009).
It is still not clear why remyelination fails in MS and a number
of putative inhibitors of myelination such as LINGO-1, Notch-
Jagged, and PSA-NCAM are frequently accused (Wang et al.,
1998a; Charles et al., 2002; Mi et al., 2005). Antagonizing LINGO-
1 in the cuprizone model enhanced differentiation of OPC and
promoted remyelination (Mi et al., 2009) and remyelination
was accelerated in ST8 alpha-N-Acetyl-Neuraminide alpha-2,8-
Sialyltransferase 4 (St8siaIV, the polysialyltransferase responsible
for PSA synthesis) knockout mice (Koutsoudaki et al., 2010), sug-
gesting that these molecular mechanisms are indeed involved in
remyelination.
MICROGLIA: CELLS WITH MANY FACES
Microglia are brain-resident mononuclear phagocytes that orig-
inate from primitive macrophages in the embryonic yolk sac
and colonize the neuroepithelium (in mice from day E9.5) at
the onset of vascularization of the CNS (Harry and Kraft, 2012;
Ginhoux et al., 2013). Microglia are active and dynamic cells,
reacting very fast upon changes in the CNS (Ransohoff and Perry,
2009) microenvironment. In the acute cuprizone model acti-
vated microglia appear already at the first 2 weeks even before
demyelination can be detected by histology and immunohis-
tochemistry (Hiremath et al., 1998) (Figure 2). After 3 weeks
activated microglia are numerously present in the CC, cortex,
and hippocampus. In the next 2–3 weeks highly activated and
proliferating microglia clear myelin debris. Once demyelination
is complete the amount of activated RCA-1 (RCA, Ricinus com-
munis agglutinin-1)/Mac-3-positive microglia starts to decrease
(Mason et al., 2004; Skripuletz et al., 2011b). In contrast, activated
microglia persist at a low level in chronically demyelinated lesions
inmice treated with cuprizone up to 12 weeks (Mason et al., 2004;
Lindner et al., 2009).
In the healthy adult brain the morphology of microglia as
well as their distribution varies between different brain regions
(Lawsonetal., 1990).Theextentofmicroglial accumulationduring
cuprizone-induceddemyelination is not uniformaswell. Probably
primarily due to the higher amount of myelin content/debris, a
significantly strongermicrogliosis canbeobserved in the cerebellar
whitematter as compared to the graymatter structures (Skripuletz
et al., 2008; Gudi et al., 2009). In the cerebellum microgliosis
occurred delayed (from week 6 to 10), but followed a white–gray
matter gradient as well (Skripuletz et al., 2010a).
In general, following stimulationwith certain cytokines in vitro
and in vivo, blood-derived monocytes can differentiate into two
subsets of peripheral macrophages, the M1 and M2 phenotype,
(Stein et al., 1992; Gordon, 2003; Edwards et al., 2006; Martinez
et al., 2008; Cassetta et al., 2011). While M1 macrophages are
involved in T helper cell type 1 (Th1) responses and the elimina-
tion of microorganisms, alternatively activated M2 macrophages
express anti-inflammatory factors, phagocytose debris and pro-
mote tissue repair. It has been suggested that microglia can also
display these two phenotypes and there is continuous debate
whether microglia play a deleterious or beneficial role in CNS
diseases (Schwartz et al., 2006; Block et al., 2007; Hanisch and
Kettenmann, 2007; Boche et al., 2013; Chhor et al., 2013). Recent
data propose that microglia can fulfill both roles and they often
display an intermediate phenotype in vivo (Olah et al., 2012;
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FIGURE 2 | Activation of microglia during the course of
cuprizone-induced demyelination (acute and chronic). Representative
coronal sections from the medial corpus callosum were stained with the
microglial marker IBA-1 (general microglial marker) and RCA-1, which
stained activated microglia. There are no activated, RCA-1-positive microglia
in control mice (A). Activated microglia could be detected in the medial
corpus callosum already after 1 week of cuprizone feeding (B). After 3
weeks of cuprizone feeding activated microglia begin to accumulate in the
corpus callosum (C). The amount of activated microglia increases upon the
course of demyelination and reaches its maximum after 5 weeks of
cuprizone treatment (D). If cuprizone is stopped after 5 weeks microglia
numbers begin to decline with the onset of remyelination at week 6 (5 + 1
week) (E). If cuprizone was fed further on to induce a chronic demyelination
a small amount of activated microglia persists until week 12 (F–H).
Voss et al., 2012; Vogel et al., 2013). Conspicuously, following
cuprizone-induced demyelination the peak of microglial activa-
tion tightly correlateswith amassive accumulationofOPC.Similar
associations are also observed in post-mortem tissue from MS
patients and in EAE challenged animals (Prineas and Connell,
1979; Nishiyama et al., 1997; Wolswijk, 2002; Patani et al., 2007).
A close relation between the presence of macrophages, inflamma-
tion, and OPC recruitment has been impressively confirmed by
Kotter and colleagues, who demonstrated a delayed OPC recruit-
ment after the depletion of macrophages via exposure of mice to
clodronate-liposomes prior/after lysolecithin-induceddemyelina-
tion. The authors linked this phenomenon to an altered growth
factor expression in macrophage-depleted animals (Kotter et al.,
2001, 2005).
In order to identify the microglia phenotype associated
either with de- or remyelination (pro-inflammatory phenotype
vs. regenerative) our group analyzed the composition of the
microglial population and expression of a subset of phago-
cytic markers and some known pro- and anti-inflammatory
cytokines in the cuprizone model (Voss et al., 2012) applying
flow cytometry (FACS) technique. The most representative type
of microglia during demyelination expressed CD11b+/CD45low
(CD, cluster of differentiation) and displayed a high ex vivo
phagocytic activity accompanied by up-regulation of several
phagocytic receptors such as Trem2b, FcγR II/III, CD36, and
Tim-3 (Voss et al., 2012) suggesting that phagocytosis is one
of the most prominent features of microglia in the cuprizone
model. The expression ofMHC class II was significantly increased
at the maximum of demyelination (week 5) in both the CC
and the cortex (Voss et al., 2012). The up-regulation of MHC-
II at the peak of demyelination may be of relevance for the
induction of remyelination since MHC-II −/− mice showed
delayed remyelination and regeneration of oligodendrocytes after
cuprizone-induced demyelination (Arnett et al., 2003). TNF-α
production was strongly increased during primary demyelina-
tion in both white and gray matter microglia. In contrast, TGF-β,
IFN-γ, IL-12, and IL-10 were not regulated (Voss et al., 2012).
On the another hand, microglia produced growth factors such as
fibroblast growth factor (FGF-2) and insulin-like growth factor I
(IGF-1) that are known to be relevant for remyelination.
Expression of the T cell co-stimulatory molecule CD80 was
only slightly increased on CD11b+/CD45low microglia during de-
and remyelination whereas CD40 and CD86 were not detected
or only marginally expressed, suggesting that the co-stimulatory
capacity of microglia in the cuprizone model was not sufficient to
activate T cells. Additionally, Olah and colleges have shown that
CD247 (B7-H1), a known immune inhibitory molecule (Magnus
et al., 2005; Ortler et al., 2008) was up-regulated on microglia
throughout de- and remyelination (Olah et al., 2012). Indeed,
in response to cuprizone a very small number of T cells was
recruited to the demyelinated CC and these T cells did not dis-
play an activated phenotype (Remington et al., 2007). Overall,
cuprizone-induced de- and remyelination are not mediated by
B or T cells, as shown by the use of RAG −/− mice that lack
lymphocytes (Arnett et al., 2001; Hiremath et al., 2008). In con-
trast, a subset of peripheral macrophages (CD11b+/CD45high)
infiltrated into the demyelinated CC of cuprizone-treated mice
(McMahon et al., 2002; Remington et al., 2007). McMahon
and colleagues transplanted green fluorescent protein (GFP)-
positive bone marrow into irradiated C57BL/6 mice and demon-
strated that macrophages constituted 1–4% of the RCA-1+ pop-
ulation at week 5–6 of cuprizone exposure (McMahon et al.,
2002). Remington and co-workers reported that only 0.5% of
the CD11b+ population is CD45high and thus represents infil-
trating macrophages. Our own study revealed that 5–7% of
CD11b+/CD45high cells were present in the CC at week 5 and 6,
even 1 week after cuprizone diet cessation (Voss et al., 2012).
The receptors CD200R and SIRP-α, suggested to inhibit acti-
vation of microglia or keep them in a resting state (Hoek et al.,
2000; Kierdorf and Prinz, 2013), were expressed on microglia at
any time either in untreated or cuprizone-challenged animals.
CD200R was rather up-regulated during early demyelination
(Voss et al., 2012). A study from Binder et al. indicates that growth
arrest gene 6 (Gas6), which is known to be a potent survival
factor for a variety of cell types, could also potentially influence
the activity of microglia by reducing proliferation and activation
of these cells (Yagami et al., 2002; Shankar et al., 2003; Binder
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et al., 2008). Gas6 is acting on three tyrosine kinase receptors
Tyro3, Axl, and Mer (Lai and Lemke, 1991). In untreated mice
Tyro3 co-localizes with CNPase. Upon cuprizone treatment Tyro3
gene expression was down-regulated and seems to coincide with
oligodendroglial loss, while Axl and Mer were found on activated
microglia (Binder et al., 2008). Since Gas6-deficient mice, chal-
lenged with cuprizone, display a potentiated demyelination and
microglia activation, one may hypothesize that upon cuprizone
treatment activation of microglia proceeds in a tightly controlled
manner by expression of an arsenal of inhibitory molecules, such
as CD200R, SIRP-α, Gas6 receptors, and Trem2.
In addition, in this model microglia seem not to be assigned to
a certain phenotype characteristic either for de- or remyelination
since most of the genes that were regulated showed an unidi-
rectional up-regulation or down-regulation throughout the de-
and remyelination processes (Olah et al., 2012) In respect to the
M1/M2 classification it seems that themicroglia population in the
cuprizone model is either heterogeneously composed of both M1
and M2 phenotypes or microglia display an intermediate status.
Altogether, the results suggest that in cuprizone-induced de-
and remyelination activated microglia play a crucial role creating
a repair promoting environment due to myelin debris clearance
proceeding in a highly controlled manner, as well as by pro-
duction of cytokines/growth factors essential for oligodendrocyte
lineage cells.
ASTROCYTES: MORE THAN GLUE
In the adult brain astrocytes fulfill a multitude of func-
tions including involvement in synaptic transmission, energy
metabolism, regulation of neurogenesis, maintenance of the
BBB and control of cerebral blood flow (Parpura et al.,
2012). Astrocytes are implicated in various CNS disorders, e.g.,
Alzheimer’s disease (Parpura et al., 2012) and demyelinating dis-
orders such as neuromyelitis optica and MS (Nair et al., 2008;
Kipp et al., 2011a). Astrocytes in MS are considered to possess a
dual role since beneficial as well as detrimental effects of astro-
cytes on de- and remyelination are being discussed (Williams
et al., 2007; Nair et al., 2008; Kipp et al., 2011a;Moore et al., 2011).
In response to different CNS pathologies astrocytes become acti-
vated whereupon GFAP-expression is increased and hypertrophy
of cellular processes occurs, a process called astrogliosis (Pekny
and Nilsson, 2005).
Already in the 1960s Carlton reported that cuprizone inges-
tion in mice led to enlargement and hyperplasia of astroglia in
brain regions that showed signs of cuprizone-induced demyeli-
nation and that astrocytosis preceded loss of myelin (Carlton,
1967). Strong astrogliosis comprising hypertrophy and hyperpla-
sia of astrocytes occurs as a response to cuprizone treatment in
different white and gray matter structures for instance the CC
(Matsushima and Morell, 2001; Gudi et al., 2009), hippocam-
pus, (Koutsoudaki et al., 2009; Norkute et al., 2009), cerebellum,
cortex (Skripuletz et al., 2008), and basal ganglia (Pott et al.,
2009). Since the CC is the most-investigated brain-region in
the cuprizone mouse model, the chronology and peculiarity of
astrocytosis will shortly be explained in this white-matter area.
Astrocytes in control animals show few, delicate and short pro-
cesses, whereas already during the first 2 weeks of cuprizone
exposure astrocytes display morphological changes and become
hypertophic with thick processes. The number of astrocytes is
not significantly increased until 3 weeks of cuprizone treat-
ment, simultaneously with first signs of apparent demyelination.
Concomitantly, astrocytes display signs of proliferation dur-
ing the course of acute demyelination (Hiremath et al., 1998;
Gudi et al., 2009). Correlating with the degree of demyelina-
tion, astrogliosis is increasing during acute demyelination peaking
around the time point of maximal demyelination and incip-
ient remyelination around 5–6 weeks of cuprizone exposure
(Hiremath et al., 1998; Gudi et al., 2009). Under continuing cupri-
zone treatment astrogliosis persists and after chronic demyeli-
nation the number of astrocytes is similar to acute demyelina-
tion (Lindner et al., 2009; Kipp et al., 2011b). Since astrocytes
show significantly lower gene and protein expression of GFAP
after chronic demyelination compared to acute demyelination,
the activation status of astrocytes appears to be higher after
acute demyelination (Ludwin, 1980; Kipp et al., 2011b). After
cessation of cuprizone treatment after acute and chronic demyeli-
nation astrogliosis is persisting over a period of weeks during
the remyelination period, which is in contrast to the transient
activation of microglia (Skripuletz et al., 2011a; Hibbits et al.,
2012). Astrogliosis is related to glial scar formation particularly in
chronic stages of MS, however, in chronic cuprizone lesions there
are no signs of astroglial scar properties (Hibbits et al., 2012).
It is well known that astrocytes produce different growth
factors during cuprizone-induced demyelination, thereby pro-
moting OPC proliferation by FGF-2 and platelet-derived growth
factor alpha (PDGFα), or regulating oligodendrocyte differen-
tiation and survival via ciliary neurotrophic factor (CNTF).
Recently, the expression of the radial glia cell marker fatty acid
binding protein 7 (FABP7) was found to be induced in acti-
vated astrocytes after cuprizone-induced acute demyelination
whereas expression of this marker and the extent of astrogliosis
was diminished after chronic demyelination (Kipp et al., 2011a).
Interestingly, the expression of FABP7 in astrocytes also corre-
lated with remyelination of lesions in EAE and MS and induced
the expression of various growth factors in vitro [FGF2, PDGFα,
and osteopontin (OPN)] indicating a potential beneficial role of
FABP7 expression in activated astrocytes for remyelination.
In a recent study from our lab, the role of astrocytes in experi-
mental demyelination was investigated by loss-of-function exper-
iments in which astrocytes where depleted in mice treated with
cuprizone (Skripuletz et al., 2013). Ablation of astrocytes during
cuprizone-induced demyelination had no impact on the loss of
mature oligodendrocytes and on axonal damage, but resulted in a
diminished activation and invasion of microglia into the demyeli-
nated lesion. As a consequence the removal of myelin debris
was delayed and subsequent OPC proliferation and remyelination
were delayed. It was concluded, that astrocytes are responsible for
the recruitment of microglia. In addition, the depletion of astro-
cytes resulted in diminished numbers of mature oligodendrocytes
during remyelination (Skripuletz et al., 2013).
A close relation between the presence of astrocytes and the effi-
ciency of remyelination has already been recognized for a long
time (Ludwin, 1980; Blakemore, 1981). However, the exact role of
astrocytes in de- and remyelination is still not fully understood.
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There is increasing evidence that astrocytes are key players in
complex interactions with OPC, mature oligodendrocytes, and
microglia supporting remyelination at least in the cuprizone
model.
CROSSTALK BETWEEN GLIA
INFLAMMATION-RELATED CYTOKINES AND MOLECULES
In the cuprizone model severe microglial accumulation and
astrogliosis are promoting an intensive inflammatory response
(Blakemore, 1972, 1973a; Hiremath et al., 1998) associated with
the expression of a battery of inflammatory cytokines and
chemokines including pro-inflammatory molecules such as TNF-
α, interleukin-1β (Il-1β), interferon- γ (IFN-γ), and nitric oxide
(NO) (Hiremath et al., 1998; Arnett et al., 2001; Mason et al.,
2001; Voss et al., 2012). A number of in vitro studies revealed that
these molecules can irreversibly harm oligodendrocytes (Selmaj
and Raine, 1988; Merrill et al., 1993; Vartanian et al., 1995;
Baerwald and Popko, 1998). However, a growing body of evidence
corroborates the assumption that an adequate and controlled
inflammatory response is required for a successful myelin regen-
eration promoting the clearance of myelin debris and stimulating
proliferation/regeneration of myelin-forming oligodendrocytes
(Diemel et al., 1998; Robinson and Miller, 1999; Arnett et al.,
2001; Kotter et al., 2001, 2005, 2006; Setzu et al., 2006; Biancotti
et al., 2008; Merson et al., 2010).
Matrix metalloproteinases (MMP), a family of zinc-dependent
endopeptidases, are highly involved in the perpetuation of inflam-
mation, myelin degradation, and remodeling of extracellular
matrix but also proposed to modulate different physiological
processes such as cellular development/growth, survival, apop-
tosis, and migration (McCawley and Matrisian, 2001; Malemud,
2006). Furthermore, MMP are shown to be implicated in numer-
ous regenerative processes (Larsen and Yong, 2004; Yong, 2005;
Lehmann et al., 2009). Previously, our group could show signifi-
cant changes in the expression of several MMP, especially during
the remyelination phase, arguing for a regulatory role of MMP in
tissue regeneration (Skuljec et al., 2011). In particular, the expres-
sion of MMP11, MMP12, and MMP3 was clearly increased dur-
ing remyelination. MMP12 was additionally up-regulated during
the demyelination phase, however, MMP7, -9, -11, -13, -15 were
either not regulated or even down-regulated during myelin clear-
ance in the CC. In contrast, the expression of endogenous antag-
onists of metalloproteinases (TIMP) was increased during the
demyelination peak between weeks 4.5 and 5. TIMP2 was found
to be expressed by microglia (Skuljec et al., 2011), whereas the
source of TIMP1 in the CNS is linked to astrocytes (Gardner and
Ghorpade, 2003). MMP3 was localized exclusively in activated
astrocytes, whereasMMP12 appeared inmicroglia, astrocytes and
during the remyelination phase in oligodendrocytes as well. The
balance between MMP and TIMP is a very critical factor for
the development/perpetuation of different pathologies (Kieseier
et al., 1999; Lindberg et al., 2001). It seems, however, that in the
cuprizone model deleterious effects of MMP and inflammatory
processes themselves are tightly controlled by TIMP. Interestingly,
the expression of MMP can be regulated by some inflammatory
cytokines, such as IL-1β or TNF-α (Dasilva and Yong, 2008).
TNF-α is a multipotent inflammatory cytokine, which can
act through two receptors, TNFR1(p55) and TNFR2(p75)
(Vandenabeele et al., 1995; Locksley et al., 2001), triggering
multiple and sometimes opposing effects (apoptosis vs. pro-
liferation). Only TNFR1(p55) possesses a cytoplasmic protein
interaction region called “death domain” and may directly induce
apoptosis via activation of different caspases. However, the sig-
naling through TNFR1(p55) is complex and can also trigger a
nuclear translocation of NF-kappa B and transcription of its
target genes including both anti-apoptotic factors (e.g., IAPs,
Bcl-2, Bcl-xL) and pro-inflammatory factors (e.g., cytokines,
chemokines) (Figiel, 2008). TNFR2(p75) responds preferentially
to membrane-bound TNF-α and does not contain a death
domain (Grell, 1995). In EAE, TNFR1(p55) is supposed to be
responsible for the detrimental effects of TNF-α by initiating
and exacerbating the course of disease while immunosuppressive
and immunoregulatory properties of TNF-α are thought to be
mediated by action through TNFR2(p75) (Eugster et al., 1999;
Suvannavejh et al., 2000; Kassiotis and Kollias, 2001). In MS, clin-
ical therapies aimed to block TNF-α-mediated pro-inflammatory
effects (Van Oosten et al., 1996; The Lenercept Multiple Sclerosis
Study Group and The University of British Columbia MS/MRI
Analysis Group, 1999; Sicotte and Voskuhl, 2001) did not yield in
an amelioration of disease and even worsened the clinical course
in some patients, strongly suggesting a bivalent role of TNF-α in
demyelination andmyelinogenesis. In the cuprizonemodel, TNF-
α was demonstrated to act as well in a bivalent manner since
TNF-α −/− mice displayed a reduced loss of oligodendrocytes
during the first 3.5 weeks of cuprizone feeding but also a signif-
icantly diminished ability to remyelinate (Arnett et al., 2001). In
this study TNFR2 but not TNFR1 has been shown to be gradually
up-regulated during de- and remyelination (Arnett et al., 2001).
Furthermore, similar to TNF-α-deficient mice TNFR2 −/− mice
displayed diminished/delayed regeneration of myelin suggesting
that beneficial effects of TNF-α on proliferation of OPC and sub-
sequent remyelination are promoted through the TNFR2 pathway
(Arnett et al., 2001). Interestingly, depletion of TNF-α did not
alter the extent of microglial or astroglial responses, however, it
displayed significant effects on expression of inflammatory genes.
In particular, several genes of the MHC-family were reduced
in the mice lacking TNF-α (Arnett et al., 2003). As already
mentioned, MHC-II −/− mice showed a delayed remyelination
and regeneration of oligodendrocytes after cuprizone-induced
demyelination (Arnett et al., 2003), again emphasizing a benefi-
cial role of the inflammatory response in the repair processes after
a demyelinating insult.
Lymphotoxin-α (Lt-α), or TNF-β, belongs to the TNF-
superfamily and acts through TNFR1, TNFR2, and lymphotoxin-
β receptor (LtβR). In the cuprizone model, Lt-α is expressed
primarily by astroglia (Plant et al., 2005) while LtβR by microglia
(Plant et al., 2007). Mice lacking Lt-α showed a decreased num-
ber of microglia and delayed demyelination as well as reduced
loss of mature oligodendrocytes at week 3.5 (Plant et al., 2005).
The course of remyelination was not influenced by this muta-
tion. However, remyelination was slightly delayed in mice lack-
ing LtβR (Plant et al., 2007). Surprisingly, remyelination was
enhanced when LtβR-signaling was inhibited by an LtβR-Ig fusion
decoy protein. These controversial results were associated with
developmental abnormalities in the immune system of LtβR
lymphotoxin-β receptor −/− mice (Plant et al., 2007).
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IL-1β is another prominent pro-inflammatory cytokine that
is produced primarily by activated microglia and macrophages
(Giulian et al., 1986; Sairanen et al., 1997). IL-1β induced pro-
liferation of astrocytes (Giulian and Lachman, 1985; Giulian
et al., 1988) and activated the production/release of different
cytokines such as TNF-α, interleukin-6 (IL-6), NO and thus
contributes to the inflammatory response. On the other hand,
IL-1β increased the secretion of growth factors promoting pro-
liferation/differentiation of OPC (Lee et al., 1995; Rothwell and
Luheshi, 2000; Vela et al., 2002; Allan et al., 2005). In the cupri-
zone model IL-1β was gradually up-regulated from the first week
of cuprizone intoxication, then strongly increased at week 3 and
sustained on this level until week 6 (Mason et al., 2001). The
cellular sources of IL-1βwereMac-1-positive microglia and a sub-
population of astrocytes. In this study Mason and colleagues have
shown that differentiation of OPC and thus, remyelination are
dramatically reduced in absence of IL-1β probably due to IL-
1β-dependent reduction of IGF-1 production, which is known
to promote differentiation of OPC and myelination (Mozell and
Mcmorris, 1991). Interestingly, accumulation of microglia and
proliferation of OPC were not altered in the IL-1β −/− mice.
Additionally, IL-1β did not display any impact on depletion of
oligodendrocytes following cuprizone treatment (Mason et al.,
2001).
The matricellular phosphorylated glycoprotein osteopontin
(OPN) is highly expressed in bone but is also secreted by a variety
of cell types including endothelial cells, activated macrophages,
leukocytes, and T cells (Murry et al., 1994; Ashkar et al., 2000;
Kury et al., 2005). OPN is known to possess multiple biological
and immunoregulatory functions being involved in cell adhe-
sion and providing a chemotactic stimulus for macrophages and
astrocytes (Denhardt and Guo, 1993; Denhardt and Noda, 1998;
Giachelli et al., 1998; Wang et al., 1998b; Sodek et al., 2000;
Mazzali et al., 2002). However, the precise role of this molecule
in the CNS is not completely understood. Previously, OPN was
shown to be up-regulated in MS lesions and in several experi-
mental animal models for demyelination including the cuprizone
model (Chabas et al., 2001; Selvaraju et al., 2004; Zhao et al.,
2008). Upon cuprizone treatment the expression of OPN was
increased on the peak of demyelination and during early remyeli-
nation in activated astrocytes and microglia. Additionally, OPN
was reported to enhance the proliferation capacity of OPC cell
lines and promote both MBP synthesis and myelin formation in
mixed cortical cultures, suggesting to be involved in remyelina-
tion (Selvaraju et al., 2004).
NO is a highly reactive molecule mainly released by activated
immune cells including microglia during different inflammatory
processes. An overproduction of NO is known to induce an irre-
versible cell damage and death in different cell populations (Chao
et al., 1992; Merrill et al., 1993). However, the role of NO in the
CNS seems to be controversial. Although in EAE the expression
level of inducible NO synthase (iNOS), an enzyme producing NO,
correlates with severity of disease and cellular infiltrate (Okuda
et al., 1995; Cross et al., 1996; Tran et al., 1997) some stud-
ies have shown even a protective role of NO. In these studies
the lack of iNOS leads to an earlier onset and more severe dis-
ease course of EAE (Fenyk-Melody et al., 1998; Sahrbacher et al.,
1998). Similar in the cuprizone model, a depletion of iNOS exac-
erbated demyelination (Arnett et al., 2002), suggesting that its role
may also include the regulation of some regenerative processes.
On the other hand, the absence of constitutively expressed neu-
ronal NO synthase (nNOS) protected the mice from cuprizone-
induced demyelination, reduced the inflammatory glial response
and oligodendroglial apoptosis, but also impaired OPC accumu-
lation and subsequent remyelination (Linares et al., 2006). The
expression of TNF-α, Il-1β, and IGF-1 was significantly decreased
in nNOS−/−mice underlining the dual role of inflammation on
de- and remyelination.
Similar contradictory observations were reported about the
impact of IFN-γ on de- and remyelination in the cuprizone
model. First Gao et al. proposed protective effects of IFN-γ on
myelin using mice that ectopically expressed a low level of IFN-γ
under the MBP promoter in oligodendrocytes (Gao et al., 2000).
In these mice reduced loss of oligodendrocytes following cupri-
zone intoxication was associated with an increase of IGF-1 expres-
sion, which is known to be protective against cytokine-mediated
oligodendroglial cell death (Ye and D’Ercole, 1999; Mason et al.,
2000b). Later, Mana et al. reported a deleterious role of IFN-γ
demonstrating reduced demyelination and enhanced remyelina-
tion in mice lacking the binding chain of the IFN-γ receptor
(Mana et al., 2006). In both cases, however, microglia were sug-
gested to be regulated by IFN-γ, since MBP/IFN-γ transgenic
animals displayed slightly elevated numbers of GFAP-positive and
RCA-1-positive glial cells already prior to cuprizone adminis-
tration (Gao et al., 2000). In contrast, in IFN-γR −/− mice
cuprizone-induced microglia accumulation was initially dimin-
ished or simply delayed (Mana et al., 2006) that was reflected at
week 3 of cuprizone diet by a reduced expression of microglia-
associated molecules such as IGF-1 and TNF-α that have been
proposed to promote proliferation of OPC. Nevertheless, Mana
et al. reported an increased number of NG2-positive cells in IFN-
γR −/− mice in comparison to wild type (wt) mice suggesting
inhibitory/harmful effects of IFN-γ on OPC recruitment/survival
and remyelination (Mana et al., 2006). In parallel, the group of
Popko reported in transgenic mice that ectopically expressed IFN-
γ under the GFAP promoter in a tetracycline-controlled manner
an altered but not inhibited recruitment/expansion of OPC via
IFN-γ-signaling. Nevertheless, the remyelination capacity was
significantly improved in mice lacking IFN-γ, probably linked to
reduced endoplasmic reticulum stress via IFN-γ (Lin et al., 2006).
In this study, a deleterious effect of IFN-γ on remyelination was
also confirmed in EAE (Lin et al., 2006). In conclusion, these con-
flicting results may allow the assumption that the effects of IFN-γ
and other pro-inflammatorymolecules, whether harmful or help-
ful, are dependent on their quantitative and temporal expression
pattern.
GROWTH FACTORS
Growth factors are known to possess pleiotropic effects in a vari-
ety of cell types including neuronal and glial cells in the CNS.
Together with chemokines, cytokines, and hormones growth fac-
tors are strongly involved in the orchestration of development,
specification, and maintenance of CNS structures. Growth fac-
tors modulate plasticity of the CNS and its repair, including
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generation of new glial and neuronal cells, their migration, pro-
liferation, maturation, and myelination. A disturbed balance of
interacting growth factors that regulate differentiation of oligo-
dendrocytes and onset of myelination may contribute to the
limited remyelination of MS plaques (Franklin and Hinks, 1999;
Miller and Mi, 2007). Gaining a clearer understanding of the
role of growth factors in de- and remyelination we assessed a
temporally detailed mRNA expression profile of different growth
factors in the cuprizone model (Gudi et al., 2011). We found
that several growth factors such as FGF-2, CNTF, IGF-1, and glial
cell-derived neurotrophic factor (GDNF) are strongly regulated
during cuprizone treatment and/or in the recovery phase.
It is widely accepted that the main impact of FGF-2 on
OPC is the induction/support of proliferation (Bansal et al.,
1996), inhibition of progenitor differentiation, and subsequent
myelination (Bansal and Pfeiffer, 1997; Goddard et al., 2001;
Murtie et al., 2005a,b; Zhou et al., 2006). In our own studies
we found that the FGF-2 mRNA expression began to increase
already from the first weeks of cuprizone feeding and was
even stronger up-regulated after 4 weeks (severe demyelina-
tion) corresponding to the intensive proliferation of OPC (Gudi
et al., 2011). Taking advantage of FGF-2 −/− mice Armstrong
et al. have shown that the absence of FGF-2 leads to a faster
regeneration/differentiation of oligodendrocytes after cuprizone-
induced demyelination (Armstrong et al., 2002). However, an
up-regulation of FGF-2 mRNA expression during remyelination
phase has been reported in lysolecithin-induced demyelination
(Hinks and Franklin, 1999) as well as in vitro in myelinating
aggregate cultures (Copelman et al., 2000). Thus, it can be sug-
gested that FGF-2 possesses multiple functions and acts not only
directly on oligodendrocytes but also influences other cell types
promoting myelination indirectly. Furthermore, FGF-2-signaling
is tightly regulated by binding to different FGF receptors and
their splice variants resulting in different modes of actions (Bansal
et al., 1996, 2003; Reuss and Von Bohlen Und Halbach, 2003;
Eswarakumar et al., 2005; Fortin et al., 2005). A recent study
of Zhou and colleagues showed that all four FGF receptors are
highly regulated upon cuprizone treatment and during remyeli-
nation (Zhou et al., 2012). In this study the authors pursued
a genetic approach with mice lacking FGFR1 in oligodendro-
cytes in a tamoxifen-dependent manner that were treated for
12 weeks with cuprizone. Previously, FGFR1 was shown to be
involved in OPC proliferation as well as in the inhibition of OPC
differentiation in vitro (Bansal et al., 1996; Zhou et al., 2006).
In Zhou et al. study after a recovery period for additional 6
weeks, OPC numbers were diminished and the number of mature
oligodendrocytes was increased, indicating a beneficial effect of
FGFR1 reduction on OPC differentiation (Zhou et al., 2012).
Additionally, an inhibitory effect of FGF-2-signaling on OPC
differentiation was observed in FGF −/− mice upon chronic
demyelination. Interestingly, FGF-2 level persisted to be elevated
until 12 weeks of cuprizone exposure, failing to potentiate pro-
liferation of OPC significantly, since both the wt mice and FGF
−/− mice displayed a similar number of OPC (Armstrong et al.,
2006), suggesting that FGF-2 may not be an essential/exclusive
mitogenic factor for OPC in vivo, and may even predominantly
promote an inhibitory effect impeding OPC differentiation and
remyelination (Armstrong et al., 2006). Although these studies
did not provide detailed insights into the responses of other glial
cells, we believe that FGF-2 modulates not solely the oligoden-
drocyte lineage but may also influence the action/interaction of
astrocytes andmicroglia. FGF-2 as well as FGFRs can be expressed
by both activated astrocytes and microglia while oligodendroglial
cells expressed mainly FGFRs (Bansal et al., 1996; Messersmith
et al., 2000; Gudi et al., 2011).
The second growth factor which has been intensively stud-
ied in the cuprizone model is platelet-derived growth factor α
(PDGFα). Being a potent mitogen for OPC PDGFα is one of
the prominent compounds of the culture medium of primary
cortical OPC derived from new-borns or embryos as well as
immortalized OPC in vitro (Noble et al., 1988; Bansal et al.,
1996). The PDGFα receptor (PDGFαR) is widely accepted as a
phenotypic marker for this developmental stage of the oligo-
dendrocytes lineage (Hart et al., 1989). Astrocytes were shown
to produce PDGFα/PDGFβ (Pringle et al., 1989) stimulating
OPC to proliferate/differentiate in vitro (Raff et al., 1988). In the
developing murine CNS PDGF was proposed to determine the
OPC population size (Calver et al., 1998; Van Heyningen et al.,
2001). To investigate the impact of PDGFα on de- and remyelina-
tion Woodruff and colleagues applied cuprizone or lysolecithin
to mice over-expressing human PDGFα under the GFAP pro-
moter in astrocytes. These transgenic mice displayed an increased
amount of OPC in steady state conditions. After a demyelinat-
ing insult due to either cuprizone or lysolecithin the OPC density
increased highly in hPDGFα-GFAPmice as compared to wt mice.
Since there was no significant enhancement of remyelination
in the lysolecithin model the authors concluded, that the OPC
density seems not to be a rate-limiting factor for a successful
remyelination (Woodruff et al., 2004). Another study showed
an impaired oligodendrocyte repopulation in PDGFαR heterozy-
gous knockout mice, caused by a reduced proliferation capacity
and overall density of OPC arguing for an important role of
PDGFαR-signaling on OPC proliferation. Differentiation of OPC
was, however, not altered in PDGFαR +/− mice (Murtie et al.,
2005b). Later, the same group reported an enhanced remyelina-
tion, increased regeneration, and reduced apoptosis of oligoden-
drocytes in the hPDGFα-GFAP mice (exploited also by Woodruff
et al., 2004) after chronic cuprizone intoxication (Vana et al.,
2007). Nevertheless, it remains unclear how PDGFα-signaling
impacts microgliosis and astrogliosis in these transgenic mice
(hPDGFα-GFAP, PDGFαR +/−), since it is known that astro-
cytes also express PDGFαR and respond to PDGFα (Besnard
et al., 1987; Fruttiger et al., 1996).
IGF-1 is believed to play a crucial role in oligodendrocyte dif-
ferentiation, survival, and myelination (Mozell and Mcmorris,
1991; Barres et al., 1992, 1993; Goddard et al., 1999; Ye and
D’Ercole, 1999). IGF-1 over-expressing mice showed hyper-
myelinated axons (Ye et al., 1995), whereas IGF-1 knockout
mice exhibited a decreased number of oligodendrocytes and
hypomyelination (Beck et al., 1995; Ye et al., 2002). The involve-
ment of IGF-1 in de- and remyelination has been reported for
various experimental demyelination models (Yao et al., 1995;
Hinks and Franklin, 1999;Mason et al., 2000b, 2003). In the CC of
cuprizone-treatedmice the expression of the IGF-1mRNA started
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to be up-regulated after 2 weeks of cuprizone feeding (Gudi et al.,
2011) and peaked at weeks 4–5 corresponding to the maximal
demyelination, proliferation of OPC and onset of their differ-
entiation (Gudi et al., 2011). Komoly et al. investigated de- and
remyelination in the cerebellar peduncles in swiss Webster mice
exposed to 0.6% (w/w) cuprizone and found an astrocytic expres-
sion of IGF-1, whereas IGF-1 receptor (IGF1R) was transiently
expressed in OPC (Komoly et al., 1992) during the early recovery
phase. In our own studies we could confirm this finding; however,
additionally we observed IGF-1 mRNA expression in activated
microglia (Voss et al., 2012). Interestingly, microgliosis was more
pronounced in mice that constantly over-expressed IGF-1 within
the brain after 3 weeks of cuprizone diet (Mason et al., 2000b).
Additionally, these mice exhibited an enhanced demyelination at
week 3 but an almost complete myelin recovery at week 5 in con-
trast to wt mice undergoing a severe myelin deficit at this time
point. Furthermore, instead of being nearly completely depleted,
mature oligodendrocytes were numerously present in the CC of
IGF-1 over-expressing mice during demyelination suggesting a
highly protective role of IGF-1 on oligodendrocytes. The posi-
tive effect of IGF-1 on mature oligodendrocyte survival was also
observed in vitro (Barres et al., 1992, 1993; Ye andD’Ercole, 1999).
Moreover, these surviving oligodendrocytes even seem to retain
the ability to remyelinate timely on week 5, regardless of remain-
ing myelin debris (Mason et al., 2000b). In conditional mouse
mutants, in which the expression of the Igf1r gene was ablated
exclusively in neurons and OPC of the cerebrum, there was a
reduced accumulation of OPC, leading to a decreased amount of
newly generated oligodendrocytes (Mason et al., 2003).
CNTF and leukemia inhibitory factor (LIF) are acting via het-
erodimeric gp130/LIFRβ (CNTF requires additionally CNTFRα)
receptor complex. Both molecules possess multiple functions in a
variety of cell types including promotion of oligodendrogenesis,
differentiation, myelin synthesis, and survival of oligodendro-
cytes (Mayer et al., 1994; Barres et al., 1996; Marmur et al.,
1998; Stankoff et al., 2002; Talbott et al., 2007; Ishibashi et al.,
2009) in vitro and in vivo and can prevent oligodendrocyte death
under pro-inflammatory conditions in vitro (Louis et al., 1993;
Vartanian et al., 1995). In cuprizone-induced demyelination LIF-
deficient mice displayed more severe demyelination, increased
loss of oligodendrocytes, and an impaired remyelination (Emery
et al., 2006; Marriott et al., 2008). Remarkably, the oligodendro-
cyte replenishment, which includes both OPC proliferation and
differentiation, seemed not to be significantly compromised in
these transgenic mice, arguing for a direct effect of LIF on dif-
ferentiated oligodendrocyte survival and myelination (Marriott
et al., 2008). Exogenously administered LIF limited cuprizone-
induced demyelination in wt mice and rescued the LIF-knockout
phenotype during cuprizone-induced demyelination. However,
remyelination was not further enhanced if wt mice were com-
plemented with LIF during the recovery phase (Marriott et al.,
2008). In our own study we were able to show that LIF mRNA
expression was up-regulated very early mainly during the first 3
weeks of cuprizone administration in both CC and cortex there-
after decreasing to normal levels in the recovery phase after toxin
withdrawal (Gudi et al., 2011). Since LIF was proposed to be
chemotactic and mitogenic for macrophages (Sugiura et al., 2000;
Kerr and Patterson, 2004) and able to stimulate myelin uptake
in vitro (Hendriks et al., 2008) it can be speculated that also in
cuprizone-induced demyelination LIF regulates microglia attrac-
tion and activation. Interestingly, LIF can inhibit the production
of the pro-inflammatory cytokine TNF-α and reactive oxygen
species (ROS) by macrophages probably limiting a progression of
inflammation and acting anti-apoptotic (Hendriks et al., 2008).
The results of the study by Sabo et al. indicated an important
role for bone morphogenic protein (BMP) in modulating oligo-
dendrogliogenesis and remyelination (Sabo et al., 2011). Several
BMPs including BMP4 belong to the transforming growth factor-
superfamily (TGF) of cytokines. TGF-β1 mRNA expression itself
was significantly enhanced during cuprizone ingestion showing
the same temporal pattern as IGF-1 (Gudi et al., 2011). OPC and
mature oligodendrocytes express BMP4 and its receptors (Kondo
and Raff, 2004). In vitro treatment of OPC with BMP4 inhibited
their differentiation but promoted differentiation of astrocytes
(Mabie et al., 1997; Grinspan et al., 2000). In vivo, the expres-
sion of BMP4 was elevated in OPC within demyelinated lesions
inducedby ethidiumbromide (Zhao et al., 2005). Similarly, in EAE
BMP4 was up-regulated upon demyelination (Ara et al., 2008),
suggesting an important role for BMP-signaling in demyelinat-
ing events. The BMP-pathway was also activated in astrocytes
and Olig2-positive cells during cuprizone-induced demyelination
(Sabo et al., 2011). An intraventricular delivery of BMP4 for 7–14
days (4–5 or 4–6 week of cuprizone diet) transiently increased
the proliferation predominantly of OPC and to a lower degree of
astrocytes and microglia. However, this augmented pool of OPC
failed todifferentiate intomatureoligodendrocytes and to enhance
remyelination, probably due to induction of apoptosis in these
cells by exogenously administered BMP4. Conversely, infusion of
Noggin, an antagonist of the BMP4-pathway, promoted matu-
ration of oligodendrocytes and potentiated remyelination in the
CC after cuprizone withdrawal (Sabo et al., 2011). However, the
sequential delivery of BMP4 between weeks 4 and 5 followed by
Noggin infusion for the following week did not improve remyeli-
nation (Sabo et al., 2013), indicating the complexity of growth
factor fine tuning and interplay.
CHEMOKINES
Chemokines were primarily postulated to regulate directional
migration of leukocytes. However, it becomes more and more
evident that different chemokines are also implicated in a vari-
ety of fundamental biological functions including proliferation,
migration, and differentiation of different cell types playing a
crucial role in development, homeostasis, and plasticity of the
immune system and the CNS (Zou et al., 1998; Bajetto et al.,
2002; Rezaie et al., 2002; Tran and Miller, 2003; Le et al., 2004;
Tran et al., 2004; Raman et al., 2011). Upon cuprizone-induced
demyelination mRNA expression of chemokine CCL3 was initi-
ated already after 2 days and then gradually increased until week
4 (McMahon et al., 2001; Buschmann et al., 2012). The defi-
ciency of this chemokine resulted in the reduced recruitment of
microglia and astrocytes as reflected by delayed demyelination
and an attenuated TNF-α secretion after 3.5 weeks of cuprizone
ingestion (McMahon et al., 2001). CCL3 has been reported to be
produced by lipopolysaccharide (LPS)-stimulated microglia and
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is implicated in the migration and activation of these glial cells
in vitro and in vivo (Hayashi et al., 1995; Cross and Woodroofe,
1999; Selenica et al., 2013). Production of CCL3 in murine corti-
cal astrocytes was also regulated after an inflammatory stimulus
such as LPS (Murphy et al., 1995).
CCL2 is another well characterized chemokine known to
be strongly implicated in the pathology of MS and EAE. In
cuprizone-induced demyelination CCL2 expression was a tran-
sient phenomenon (McMahon et al., 2001; Buschmann et al.,
2012) being significantly up-regulated particularly during the first
week of cuprizone exposure. CCL2 has been shown to be pro-
duced by astrocytes in EAE (Ransohoff et al., 1993; Adamus
et al., 1997). LPS, IL-1β, and TNF-α-induced CCL2 secretion
by astrocytes, but not microglia in vitro (Hayashi et al., 1995).
Additionally, this study showed that CCL2 induces chemotaxis
of microglia. EAE studies using neutralizing antibodies against
CCL2 and CCL3 suggested that CCL3 controls accumulation of
mononuclear cell during acute EAE, correlating with increasing
acute disease severity, while CCL2 was responsible for a mononu-
clear cell infiltration during relapsing EAE (Karpus et al., 1995;
Kennedy et al., 1998). Thus, it might be proposed that in the
cuprizone model CCL2 modulates an early attraction or activa-
tion of microglia to the lesion site, while CCL3 plays an important
role in later stages, possibly promoting proliferation or initia-
tion of phagocytosis of myelin debris. In line with other studies
(McMahon et al., 2001; Buschmann et al., 2012) we could also
detect an up-regulated expression of CCL2 and CCL3 upon cupri-
zone treatment (Skripuletz et al., 2013). Interestingly, a partial
ablation of astrocytes in mice challenged for 3 weeks with cupri-
zone did not reveal any difference in CCL2 and CCL3 expression,
suggesting that these cytokines are not astrocyte-derived at least
at this time point (Skripuletz et al., 2013). However, the clear-
ance of damaged myelin as well as the recruitment of microglia
was strongly impaired in this experimental setting, arguing for
astrocyte-derived factors that mediate attraction of microglia.
Our studies suggested that this process may be regulated by
the chemokine CXCL10 since CXCL10 mRNA expression was
reduced in the astrocyte-depleted mice and the treatment of
astrocyte cultures with LPS, IL-1β, or TNF-α led to an enhance-
ment of CXCL10 production in vitro (Skripuletz et al., 2013).
The chemokine CXCL12 is a potent chemoattractant for lym-
phocytes and monocytes but not neutrophils (Bleul et al., 1996).
CXCL12–CXCR4-signaling plays an important role in the pat-
terning and plasticity of both immune and nervous system during
development and adulthood (Klein and Rubin, 2004; Li and
Ransohoff, 2008). In the adult CNS, CXCL12 orchestrates neuro-
transmission, neurotoxicity and neuroglial interactions (Lazarini
et al., 2003). Activation of the CXCR4 cascade in OPC leads
to migration, proliferation, and differentiation of these cells
(Dziembowska et al., 2005; Kadi et al., 2006; Maysami et al.,
2006). The cellular source of CXCL12within the CC of cuprizone-
treated mice includes both GFAP-positive astrocytes and CD11b-
positive microglia. CXCR4 was located on NG-2-positive OPC.
Loss of CXCR4-signaling via either pharmacological blockade
or in vivo RNA-silencing led to reduced OPC maturation and
remyelination failure in the cuprizone model (Patel et al., 2010).
Astrocytic expression of CXCL12 was detected in MS lesions
and could be as well induced upon IL-1β, TNF-α, and MBP
stimulation in vitro (Ambrosini et al., 2005; Calderon et al.,
2006). Activated astrocytes are armed with both TNFR1 and
TNFR2. Interestingly, mice lacking TNFR2 displayed a loss of
CXCL12 up-regulation in astrocytes and concomitant reduction
in the number of NG2- CXCR4-positive OPC leading to delayed
remyelination in the cuprizone model (Patel et al., 2012). The
lentiviral-gene delivery of CXCL12 into TNFR2 −/− mice could
rescue this effect, suggesting a TNF-α-mediated mechanism of
remyelination via astrocytic CXCL12 (Patel et al., 2012).
IS THE CUPRIZONE MODEL RELEVANT FOR MS RESEARCH?
LIMITATION AND STRENGTH OF DIFFERENT ANIMAL
MODELS
Since dysfunctions of the immune system are supposed to be the
main compound in the pathology of MS, most currently available
MS therapies focus on the suppression or control of immune-
mediated mechanisms. However, the aetiology ofMS remains still
unresolved and the pathology of MS lesions as well as the individ-
ual course of disease are highly heterogeneous (Lucchinetti et al.,
2000; Lassmann et al., 2007). Moreover, known immunosuppres-
sive therapeutics that are quite effective in relapsing-remitting
MS (RRMS) extend limited beneficial effects during late stages of
secondary-progressive (SPMS) and primary-progressive (PPMS)
MS subtypes (Bradl and Lassmann, 2009). Therefore, the focus
in MS research is directed towards the development of indi-
vidual MS therapies and the establishment of new regenerative
agents that support repair mechanisms (Lucchinetti et al., 1997;
Stangel and Hartung, 2002; Huang et al., 2011; Zhang et al.,
2011; Hagemeier et al., 2012; Franklin and Gallo, 2014). Probably
the most promising approach for MS treatment would include
an immunomodulatory, protective, and regenerative compound
(Zhornitsky et al., 2013). A broad spectrum of animal mod-
els is available to develop and test such therapies and methods.
However, since the pathomechanisms of MS are highly complex
none of these models reflects the whole spectrum of MS and
due to an artificial way of induction all these models have their
limitation (Table 1). EAE reflects the autoimmune origin of MS
and is probably the most frequently used model that already
has been proven as extremely useful to develop/establish/test
some of the currently available immunomodulating MS thera-
peutics (Gold et al., 2000, 2006; Constantinescu et al., 2011).
Since multiple environmental factors such as Epstein-Barr Virus
(EBV) infections were suggested to be strongly linked to the
development of MS viral animal models, such as Semliki Forest
virus (SFV), mouse hepatitis virus (MHV), or Theiler’s murine
encephalomyelitis virus (TMEV) demyelination models may be
helpful to address this hypothesis (Suckling et al., 1978; Serafini
et al., 2007; Drescher and Sosnowska, 2008; Lane and Hosking,
2010; Tsunoda and Fujinami, 2010). Genetic models are useful to
study dysfunctions of myelination and axonal transport but they
are not suitable to investigate remyelination. The assessment of
remyelination is complicated in EAE and in virus mediated mod-
els due to concurrently occurring de- and remyelination. Thus,
the evaluation of efficiency of remyelination-boosting factors
might by limited. Another drawback of autoimmune-induced
demyelination is the unpredictable localization of lesions that
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Table 1 | Advantages and disadvantages of different animal models available to study the broad spectrum of MS-relevant processes.
Induction Animal models Strength Limitation




myelin reactive T cells]
-is the most frequently used model to study
autoimmune encephalitis in the CNS
-mimics MS with respect to clinical symptoms and
pathology
-there is a broad spectrum of EAE induction
protocols, allowing to study different aspects of
MS
-displays a relatively sensitive read-out system
-is mainly useful to test putative
immunosuppressive and neuroprotective drugs, to
study the behavior of different T cells subtypes,
mechanisms of neuronal damage and loss,
reactions of resident glial cells and their interplay
with peripheral immune cells, to investigate the
role of different molecular factors on T cells
activation and to study BBB dysfunctions
-an artificially induced sensitisation to myelin
compounds -typically requires an application of
adjuvant to activate the innate immune system
-there is probably a different way of T cells priming
as compared to MS
-high complexity due to involvement of different
cell types
-high variety in susceptibility to EAE in dependence
of strains, gender, species or even different animal
colonies potentially leading to discrepancies in
different EAE studies
-does not reflect aspects of progressive MS
-the assessment of remyelination is at least
problematic since both de- and remyelination can
proceed simultaneously
-unpredictable localisation of lesions that classically






-supports the environmental compound (early
infections) of MS aetiology
-allows to study the phenomenon of epitope
spreading
-useful to study mechanisms of viral infection of
neuronal and glial cells as well as a viral
persistence
-useful to study immune-mediated and
virus-triggered demyelination but also to test
different regenerative, neuroprotective, and
immunosuppressive therapeutics
-the assessment of remyelination is at least
problematic since both de-and remyelination can
proceed simultaneously
-some protocols require surgery
-TMEV is time consuming and can be induced only
in mice
-C57BL/6 mice clear TMEV → difficulties in use
genetically modified strains that are mostly
development in the C57BL/6 background
Toxic Cuprizone (systemic oral
application)
-well reproducible, established model
-predictable kinetics of de- and remyelination
-clear detection/evaluation system
-simple induction protocol
-de- and remyelination take place in different
regions and in both white and gray matter
following different spatial and temporal pattern
-can be induced in different rodents and strains
-available as an acute and chronic demyelination
model
-useful to study remyelination and cellular behavior
in the absence of peripheral immune cells
-an artificial way of demyelination induction due to
an irreversible damage of mature oligodendrocytes
via a toxin of unknown mode of action
-T, B cells independent → only of limited relevance
for MS and the development of
immunomodulating drugs
-BBB remains intact
-clinical symptoms only purely reflect MS; no good
clinical read-out
-time consuming (acute model: 5–8 weeks;
chronic: 12–16 weeks)
-not useful to study spinal cord demyelination since




-well reproducible, established model
-predictable kinetics of de- and remyelination
-well known lesion site can be induced in brain or
spinal cord
-useful to study remyelination and cellular behavior
-useful to test putative immunosuppressive,
neuroprotective, and especially regenerative
agents
-an artificial way of demyelination induction due to
an irreversible selective damage of myelin
producing cells in the lysolecithin model. Ethidium
bromide damages all nucleolus containing cells.
-T, B cells independent → only of limited relevance
for MS
-tissue damage due to injection procedure
-high complexity and difficulties in the assessment
of remyelination in the spinal cord since different
myelinating cells are involved in the remyelination
Genetic Jimpy, Shiverer (shi),
Rumpshaker mice
-consistency in myelination defects
-useful to study dysfunctions of myelination,
neuronal and glial behavior
-non inflammatory models
-poor relevance for MS
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FIGURE 3 | Growth factors, cytokines, chemokines, and MMP expressed
in the medial corpus callosum during cuprizone-induced de- and
remyelination. The expression (mostly mRNA expression) of different
growth factors, cytokines, chemokines, and MMP were summarized from
different studies where 0.2% (w/w) cuprizone was fed for 5 to 8–10-week old
C57BL/6 mice (Mason et al., 2000a; McMahon et al., 2001; Selvaraju et al.,
2004; Gudi et al., 2011; Skuljec et al., 2011; Buschmann et al., 2012; Voss
et al., 2012; Skripuletz et al., 2013). The expression of various factors is linked
to the cellular response during de- and remyelination. Asterisks marked the
maximal expression of factors in certain weeks.
classically occur in the spinal cord. In the toxic animal models
such as lysolecithin and ethidium bromide models, a focal myelin
loss is induced by stereotactic injection of the toxic compound
into the selected region of the CNS (Yajima and Suzuki, 1979;
Woodruff and Franklin, 1999). Toxic models are commonly used
to study remyelination since their kinetics are well predictable
and the lesion site is known. Another plus of these models is a
clear read-out of remyelination since significant improvements of
remyelination can be gradually reflected by functional recovery
of the animals. One of the major drawbacks of these models is
the need of an exact stereotactic surgical procedure. Furthermore,
the application of the toxin produces a stab wound that may
complicate the molecular processes. In contrast, a systemic oral
administration of the toxin cuprizone does not require com-
plicated equipment/certain surgical skills and is represented by
a relatively simple, but as well highly reproducible and reliable
protocol. However, the question arises whether cuprizone treat-
ment represents a model for MS. Since lesion induction is not
immune-mediated it is quite different to MS. Thus, similar to
other toxin-induced demyelination models, lesion induction is
probably not relevant to MS although some authors suggest that
demyelination primarily induced by oligodendroglial damage
linked to mitochondrial dysfunctions, as seen in MS pattern III
and IV lesions, is mimicked by the cuprizone model (Torkildsen
et al., 2008; Kipp et al., 2009; Liu et al., 2010; Veto et al., 2010;
Acs and Komoly, 2012; Kang et al., 2012). Moreover, since recent
studies have shown that the de- and remyelination extend as well
the cellular composition seems to differ between white and gray
matterMS lesions (Bo et al., 2003; Albert et al., 2007; VanHorssen
et al., 2007) the cuprizone model becomes increasingly attractive
to study the underlying pathophysiological mechanisms of de-
and remyelination to uncover regional differences (Gudi et al.,
2009; Pott et al., 2009; Schmidt et al., 2013). Cuprizone treatment
is a good model to study remyelination and to answer general
neurobiological questions of glial reactions after a demyelinat-
ing insult (Skripuletz et al., 2011a, 2013; Zendedel et al., 2013).
Furthermore, the cuprizone model allows to dissect the molec-
ular mechanisms without the interference with the peripheral
immune system, which is rather difficult in EAE. Frequently the
model is used in parallel to EAE or other animal models to study
treatment effects of substances that promote remyelination, such
as benztropine, quentiapine fumarate, or antagonists of LINGO-1
(Mi et al., 2009; Deshmukh et al., 2013; Zhornitsky et al., 2013).
LESSONS LEARNED AND PRACTICAL SUGGESTIONS
There are different protocols for the duration of cuprizone treat-
ment, concentration of cuprizone used, and time points of
investigations which leads to difficulties in the interpretation
of the data. Many investigators feed C57BL/6 mice with 0.2%
(w/w) cuprizone for 6 weeks to achieve complete demyelination.
However, it was already described in the early work by the group
of Matsushima and confirmed by others that complete demyeli-
nation of the CC occurs at week 5 of cuprizone feeding. Despite
continued cuprizone exposure mature oligodendrocytes occur
between week 5 and 6 and start subtle remyelination.When cupri-
zone is fed even longer these oligodendrocytes are damaged again
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and the myelin disappears after week 6. Thus, it should be kept
in mind that remyelination does not strictly start with the end
of cuprizone administration but all the necessary prerequisites
are already made available before that. A recent study provided
insights that even 2–3 weeks of cuprizone ingestion is sufficient to
induce glial responses and de- and remyelination pattern similar
to that described for 5–6 week treatment (Doan et al., 2013).
In summary, the following practical lessons can be learned
from the studies published in the past 50 years:
1. Most studies in this model were performed in mice, but rats,
guinea pigs, and hamsters are also susceptible to cuprizone.
2. Cuprizone is usually administrated mixed in the powdered
rodent chow. Cuprizone containing pellets are also possible.
However, since cuprizone is a heat sensitive compound, it is
important to pay attention to temperature conditions when
preparing the pellets.
3. The extent of cuprizone-induced demyelination is mouse
strain specific. In the last two decades mice of the C57BL/6
background were mainly used for investigations and are thus
the best-characterized strain. When using other strains the
controls need to be characterized carefully.
4. Cuprizone-induced demyelination is age-, and in some
strains also gender-dependent. Usually young (8–10 weeks)
male C57BL/6 mice are used in the cuprizone model.
5. The dose of cuprizone needs to be adjusted in accordance to
species, mouse strains, and age of animals. For young male
C57BL/6 mice (8–10 weeks old) the cuprizone dose of 0.2%
(w/w) is known to be well tolerated and reliable to induce a
profound demyelination. When using other doses again the
controls need to be well characterized since comparison to
most published studies is not possible.
6. Demyelination in the cuprizone model is region-dependent.
Most studies have investigated the medial CC where com-
plete demyelination occurs after 5 weeks of 0.2% (w/w)
cuprizone administration. We therefore, recommend to stop
cuprizone after 5 weeks. However, complete demyelination
in the cortex or the hippocampus is reached after 6 weeks
of cuprizone feeding and thus the duration of treatment
needs to be adjusted according to the region to be inves-
tigated. The spatiotemporal pattern of cuprizone-induced
de- and remyelination is brain region specific and may even
vary within a structure like the CC. Therefore, it is of great
importance to always investigate a similar bregma level in all
animals.
7. Remyelination is fast and robust after acute demyelination
(cuprizone feeding for 5 weeks). Thus, in young mice dif-
ferences may be picked up only early at 0.5 or 1 week after
stopping cuprizone feeding since smaller effects may be com-
pensated at later time points. After chronic demyelination (12
weeks) the remyelination capacity retains after withdrawal
from the cuprizone diet but is strongly decreased.
8. Different myelin proteins are temporally individually
degraded and re-expressed. Knowledge of this pattern is
required to plan and interpret the experiments.
9. In order to generate sustainable conclusions it is important
to investigate several time points and chose them carefully
depending on the question to be answered.
FIGURE 4 | Cellular and molecular response in the medial corpus
callosum during cuprizone-induced de- and remyelination. (A)
Distribution of glial cells under normal conditions. (B) Weeks 1–3, “early
demyelination.” Mature oligodendrocytes begin to undergo apoptosis
already during the first week of cuprizone feeding. Microglia are highly
motile cells. They may detect apoptotic oligodendrocytes and initiate
together with astrocytes numerous inflammatory and probably also
reparative processes. Various chemokines, cytokines, and growth factors,
promoting attraction and activation of microglia and astrocytes but also
migration of OPC are produced during the first week of cuprizone
treatment. In the next 2 weeks of the “early demyelination” period
inflammatory cytokines are already slightly up-regulated and maintain the
inflammatory cycle by further promoting activation and proliferation of
astrocytes and microglia but probably harming oligodendrocytes as well.
Oligodendrocytes are almost completely depleted at week 3 of cuprizone
treatment. (C) Weeks 3.5–5, “severe demyelination.” Activated microglia
begin to clear myelin debris. Several MMP, chemokines, cytokines, and
growth factors produced by activated astrocytes and microglia are
supporting phagocytosis and promoting proliferation of OPC. At week 5
nearly all axons in the medial corpus callosum are demyelinated. (D) Weeks
5–6 “early remyelination.” In this week the amount of activated microglia
begins to decline. Astrocytes are still activated but change their
morphology. OPC differentiate and begin to remyelinate nude axons.
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10. Models using additional inhibitors of proliferation like
rapamycin in order to better synchronize remyelination are
not well characterized. Such substances also affect microglia
and astrocytes the reaction of which has not been character-
ized so far. Thus, the system is even more artificial and the
interpretation of results may be impossible because beside the
oligodendrocyte damage there is interference with all other
proliferating cells.
CONCLUSION
The cuprizone model is a well established and investigated
paradigm to study de- and remyelination in rodents. It seems that
the regeneration program initiated after the toxic insult via cupri-
zone proceeds in a highly controlled manner running sequences
of tightly orchestrated events on molecular and cellular levels
beginning with an activation of microglia and astrocytes as a
response to the oligodendrocyte insult within the first 3 weeks of
cuprizone feeding followed by a massive proliferation of all glial
cells and myelin clearance between the third and fifth week, and
onset of remyelination around week 5.5 (Figures 3, 4). There is
growing evidence that in particular a limited inflammation may
play a beneficial role in oligodendroglial regeneration and is even
a preamble for successful remyelination. Activated microglia and
astrocytes are sources of most factors. Microglia seem to be cru-
cial for remyelination by promoting phagocytosis of myelin debris
and production of factors regulating development of oligoden-
droglial cells. The role of astrocytes in the cuprizone model is
still not completely elucidated. However, more and more stud-
ies emerge postulating astrocytes as a central cell type supporting
a number of regenerative processes.
Although well characterized the cuprizone model lacks the
autoimmune component of MS. Thus, it possesses only a lim-
ited spectrum of MS-relevant mechanisms in particular in lesion
induction. However, it is useful to study T cells-independent de-
and especially remyelination as well as basic myelin repair mech-
anisms, interaction of glial cells and their communications with
axons. Since no animal model covers the complex pathomecha-
nisms of humanMS, the various animal models should be applied
selectively or complementary to investigateMS-relevant processes
and develop putative regenerative and protective treatments com-
plementing immunomodulating therapies.
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